CDER’s Office of Compliance Kicks Off Annual Report Season with Rundown of 2023’s Major Public Health Enforcement Initiatives
FDA Law Blog: Biosimilars
JANUARY 22, 2024
Claud — The Office of Compliance (OC) at FDA’s Center for Drug Evaluation and Research (CDER) had a role in many of the major public health enforcement matters you may have read about last year. This is another area in which FDA works with industry to try to ensure voluntary compliance from regulated entities. By John W.M.
Let's personalize your content